OCMS Bio

Name

OCMS Bio

Legal name

OCMS Bio, LLC

Website

https://ocms.bio

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Therapeutic Antibody Discovery and Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA), Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE), High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA)

Keywords

• Monoclonal antibody discovery
• Therapeutic antibody development
• Antibody library screening
• AI-designed antibody libraries
• Preclinical antibody pipeline

Headquarters

HQ city

Malvern

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Therapeutic Antibody Development and Licensing: OCMS Bio develops proprietary antibody therapeutics through its pipeline (OB-24-01, OB-24-02, OB-25-01, OB-25-02) targeting infectious diseases, metabolism, oncology, and autoimmune disorders. Revenue would be generated through licensing deals, partnerships with pharmaceutical companies, or eventual product commercialization.
2. Technology Platform Partnerships: The company offers access to its OCMS platform technology for pharmaceutical partners seeking accelerated antibody discovery services, generating revenue through platform licensing and collaboration agreements.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

OCMS Bio discovers and develops therapeutic monoclonal antibodies using its proprietary OCMS (On-Cell mAb Screening) platform combined with AI-designed de novo antibody libraries. The company operates a preclinical pipeline of four candidates and provides pharmaceutical partners with access to its discovery platform and antibody assets through licensing arrangements.

Product overview

OCMS Bio is an antibody discovery and engineering company offering a unified platform plus pipeline products. The core offering is the On-Cell mAb Screening (OCMS) Platform, a proprietary high-throughput mammalian cell-based screening technology that identifies antibodies based on functional activity rather than traditional binding affinity metrics. This platform enables screening of 100,000+ antibody variants in parallel while preserving native heavy-light chain pairings. The company's pipeline includes four therapeutic candidates: OB-24-01 (long-acting RSV antibody), OB-24-02 (ActRIIA/B targeting metabolism antibody), OB-25-01 (undisclosed orphan drug), and OB-25-02 (undisclosed oncology ADC). The platform and pipeline products are integrated through the company's function-first discovery approach designed to generate best-in-class biologics.

Differentiator

Problem solved

Functional benefit

Products and services

• OCMS Antibody Discovery Platform Proprietary on-cell monoclonal antibody screening service that screens antibody candidates directly against targets in their native cell-surface context, available to pharmaceutical and biotechnology partners for outsourced discovery campaigns.
• AI-Designed De Novo Antibody Libraries
• OB-24-01 (RSV Antibody Candidate) Preclinical-stage monoclonal antibody candidate targeting respiratory syncytial virus (RSV), available for out-licensing to pharmaceutical partners.
• OB-24-02 (ActRIIA/B Antibody Candidate) Preclinical-stage monoclonal antibody candidate targeting ActRIIA/B receptors for metabolic disease applications, available for out-licensing to pharmaceutical partners.
• OB-25-01 (Rare Autoimmune Antibody Candidate) Preclinical-stage monoclonal antibody candidate targeting a rare autoimmune indication with orphan drug potential, available for out-licensing to pharmaceutical partners.
• OB-25-02 (Oncology ADC Candidate) Preclinical-stage antibody candidate developed as an antibody-drug conjugate (ADC) for oncology applications, available for out-licensing to pharmaceutical partners.

Quantifiable outcome

• Screens 100,000+ antibody variants in parallel
• +2 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Partner Company (Undisclosed)coreStrategic or Co-development Partner · 18 November 2024OCMS Bio collaborated with a partner company to successfully screen a large AI-designed antibody library, demonstrating the power of its On-Cell mAb Screening (OCMS) platform to accelerate antibody discovery. This collaboration provided critical insights into antibody ranking, function, and further refinement of AI-driven design methodologies.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Absci: Public AI-driven generative antibody design company combining zero-shot AI design with high-throughput wet-lab validation. Comparable as a direct competitor using AI + high-throughput screening to accelerate therapeutic antibody discovery.
• BigHat Biosciences: AI/ML-driven antibody design and discovery platform integrating generative AI with high-throughput laboratory screening. Comparable emerging player pursuing similar AI + functional screening thesis.
• AbCellera Biologics: NASDAQ-listed antibody discovery platform combining high-throughput single-cell screening with AI/ML for therapeutic antibody identification. Directly comparable as a platform-first antibody discovery company pursuing pharma partnerships and an internal pipeline.
• Adimab: Leading independent antibody discovery platform offering yeast-based and mammalian-based discovery services to pharma partners. Closely comparable as a platform-licensing antibody discovery business with a similar B2B pharma partnership GTM motion.
• Alloy Therapeutics: Biotech platform company providing antibody discovery services, libraries, and licensing infrastructure to pharma and biotech partners. Comparable as a B2B antibody discovery platform with licensing-driven revenue model.

Broad incumbents

• GenScript: Global biotech providing antibody discovery, protein engineering, and CDMO services alongside broader gene synthesis. Comparable as an incumbent offering antibody discovery services and platform partnerships to pharma/biotech.
• Bio-Techne: Large public life-sciences tools and reagents company with significant antibody-related reagents, assays, and discovery services. Comparable as an incumbent providing antibody research tools and adjacent services to pharma/biotech customers.

Emerging players

• Ginkgo Bioworks: Public synthetic biology platform offering cell engineering and bioprocessing services to pharma and industrial biotech customers. Comparable as a platform-as-a-service biotech pursuing pharma partnerships, though broader than pure antibody discovery.
• Generate Biomedicines: Generative AI biologics platform developing de novo protein therapeutics, including antibodies. Comparable as an emerging AI-driven biologic discovery company with both partnered and internal programs.
• Immunome: NASDAQ-listed antibody discovery and development company co-founded by OCMS founder Dr. Scott Dessain. Comparable as an antibody-focused clinical-stage company that emerged from similar scientific leadership, providing a reference point for the founder's prior playbook.

Market position

Strengths5 records

Weaknesses2 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ocms-bio

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OCMS Bio